Screening of soy protein-derived hypotriglyceridemic di-peptides in vitro and in vivo by Inoue, Nao et al.
RESEARCH Open Access
Screening of soy protein-derived
hypotriglyceridemic di-peptides in vitro and
in vivo
Nao Inoue
1,4†, Koji Nagao
1†, Kotaro Sakata
1, Naomi Yamano
1, Pathma Elgoda Ranawakage Gunawardena
1,
Seo-Young Han
1, Toshiro Matsui
2, Toshihiro Nakamori
3, Hitoshi Furuta
3, Kiyoharu Takamatsu
3 and
Teruyoshi Yanagita
1*
Abstract
Background: Soy protein and soy peptides have attracted considerable attention because of their potentially
beneficial biological properties, including antihypertensive, anticarcinogenic, and hypolipidemic effects. Although
soy protein isolate contains several bioactive peptides that have distinct physiological activities in lipid metabolism,
it is not clear which peptide sequences are responsible for the triglyceride (TG)-lowering effects. In the present
study, we investigated the effects of soy protein-derived peptides on lipid metabolism, especially TG metabolism,
in HepG2 cells and obese Otsuka Long-Evans Tokushima fatty (OLETF) rats.
Results: In the first experiment, we found that soy crude peptide (SCP)-LD3, which was prepared by hydrolyze of
soy protein isolate with endo-type protease, showed hypolipidemic effects in HepG2 cells and OLETF rats. In the
second experiment, we found that hydrophilic fraction, separated from SCP-LD3 with hydrophobic synthetic
absorbent, revealed lipid-lowering effects in HepG2 cells and OLETF rats. In the third experiment, we found that
Fraction-C (Frc-C) peptides, fractionated from hydrophilic peptides by gel permeation chromatography-high
performance liquid chromatography, significantly reduced TG synthesis and apolipoprotein B (apoB) secretion in
HepG2 cells. In the fourth experiment, we found that the fraction with 0.1% trifluoroacetic acid, isolated from Frc-C
peptides by octadecylsilyl column chromatography, showed hypolipidemic effects in HepG2 cells. In the final
experiment, we found that 3 di-peptides, Lys-Ala, Val-Lys, and Ser-Tyr, reduced TG synthesis, and Ser-Tyr
additionally reduced apoB secretion in HepG2 cells.
Conclusion: Novel active peptides with TG-lowering effects from soy protein have been isolated.
Background
In industrialized countries, lifestyle-related diseases such
as hyperlipidemia, arteriosclerosis, diabetes mellitus, and
hypertension are widespread and increasingly prevalent,
thus contributing to the increases in cardiovascular
morbidity and mortality [1,2]. Accompanied by the
rapid increase in the number of elderly people, this
increase in lifestyle-related diseases becomes important
not only medically, but also socioeconomically. A clus-
tering of metabolic disorders in an individual, defined as
metabolic syndrome, is known to increase cardiovascular
morbidity and mortality. Although the pathogenesis of
metabolic syndrome is complicated and the precise
details of its underlying mechanisms are not known,
lipid abnormality is now proposed as a feature of meta-
bolic syndrome along with insulin resistance [1-3].
Many studies have suggested that the quality of dietary
proteins can be an important modulator of the risks
associated with this syndrome [4-7].
In general, plant protein intake is inversely related to
the risk of hypertension and cardiovascular disease
[4-7]. For example, several studies have shown that diet-
ary soy protein reduces cholesterol and triglyceride (TG)
levels and lowers blood pressure in animals and humans
[4-9]. Because it has been reported that peptides or
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intact proteins or amino acid mixtures [10,11], bioactive
peptides have been produced in vitro through chemical
or enzymatic hydrolysis of several food proteins, in
order to modify and improve the physiological functions
of dietary proteins [11,12]. Bioactive peptides are pre-
p a r e df r o mb o t hp l a n ta n da n i m a ls o u r c e s ,w i t ht h e
antihypertensive peptides IAP and VY and the hypocho-
lesterolemic peptide IIAEK derived from wheat gliadin,
sardine muscle, and bovine milk a-lactoglobulin, respec-
tively [13-17]. For soy protein, several bioactive peptides,
including the hypocholesterolemic peptide LPYPR, anti-
hypertensive peptide NWGPLV, antioxidant peptide
LLPHH, and anti-obese peptide VRIRLLQRFNKRS,
were derived from its major constituents, glycinin and
b-conglycinin (BCG) [18-21]. Of the limited number of
peptides reported to have hypotrigliceridemic activities,
VVYP, VYP, and VTL were identified in hydrolyzed glo-
bin from animal blood [22].
In the present study, we investigated the effects of soy
protein-derived peptides on hepatic lipid metabolism,
especially TG metabolism, both in vitro and in vivo.W e
used human hepatoma HepG2 cells, the most suitable
and accessible human-derived cells that retain many of
the biochemical functions of human liver parenchymal
cells [23], for the in vitro study. For the in vivo study,
Otsuka Long-Evans Tokushima fatty (OLETF) rats,
which develop a syndrome with multiple metabolic and
hormonal disorders that shares many features of human
obesity, were used. OLETF rats exhibit hyperphagia,
owing to the lack of cholecystokinin receptors; as a
result, they become obese and develop hyperlipidemia,
fatty liver, and diabetes [24-26].
Materials and methods
Preparation of soy peptides
Preparation of soy crude peptides (SCP)-LD3 was per-
formed by hydrolyze of soy protein isolate with endo-type
protease derived from Bacillus sp. and fractionation with
centrifugation [27]. SCP-LD3 was separated into 2 frac-
tions (hydrophobic fraction and hydrophilic fraction) on
the basis of hydrophobicity by using hydrophobic synthetic
absorbent (DIAION HP21; Mitsubishi Chemical Corpora-
tion, Tokyo, Japan). The amino acid composition of SCP-
LD3, hydrophobic fraction, and hydrophilic fraction was
analyzed with an automatic amino acid analyzer; results
are shown in Table 1. Hydrophilic fraction was further
fractionated by gel permeation chromatography-high per-
formance liquid chromatography (GPC-HPLC, Bio-Rad
Superdex Peptide HR10/30 column, 30% CH3CN/0.1% tri-
fluoroacetic acid (TFA), 0.3 mL/min), and di- or tri-pep-
tide fractions were collected at an elution time ranging
from 45 to 75 min (Figure 1; Fraction A, Frc-A, 45-55
min; Fraction B, Frc-B, 55-65 min; Fraction C, Frc-C,
65-75 min). Then, 2 peptide fractions (0% CH3CN/0.1%
TFA and 20% CH3CN/0.1% TFA fractions) were obtained
by octadecylsilyl (ODS) open-column chromatography
(20 × 60 mm) from Frc-C peptides. Finally, 0% CH3CN/
0.1% TFA fraction peptides were separated by reversed-
phase HPLC (COSMOSIL 5C18-AR-II column; Nakalai
tesque, Kyoto, Japan), and 7 di-peptides (Figure 2;
Table 1 Amino acid composition of soy peptides
Amino
acid
Soy crude
peptide-LD3
Hydrophobic
peptide
Hydrophilic
peptide
(%)
Val 3.78 4.84 4.00
Ile 3.81 5.98 3.15
Leu 8.00 5.41 8.61
Lys 6.20 5.35 7.15
Met 1.50 1.47 1.00
Phe 4.86 8.20 2.80
Thr 4.07 3.45 3.84
Trp - - -
His 2.97 3.05 2.99
Tyr 4.19 4.87 2.32
Cys 1.08 1.50 1.13
Asx 12.11 11.33 12.62
Glx 20.38 13.28 27.14
Pro 5.52 8.23 4.73
Gly 3.82 3.94 4.12
Ser 5.56 4.25 5.52
Ala 4.10 2.94 4.42
Arg 8.11 8.71 7.66
Tryptophan content could not be determined under the present experimental
condition.
Figure 1 Calibration of Superdex Peptide HR10/30 gel
permeation chromatography column by using standard
peptides and the elution profile of the hydrophilic fraction of
soy crude peptide-LD3.
Inoue et al. Lipids in Health and Disease 2011, 10:85
http://www.lipidworld.com/content/10/1/85
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Val-Lys) were identified. These di-peptides, except Leu-
Val, could be synthesized using a Fmoc solid-phase synth-
esis method according to the manufacturer’s instructions
(Kokusan Chemicals, Osaka, Japan). The sequence of the
di-peptides was confirmed on a PPSQ-21 amino acid
sequencer (Shimadzu Co., Kyoto, Japan).
Cell culture
HepG2 cells were maintained in Dulbeccos’sm o d i f i e d
Eagle’s medium (DMEM) containing 100 units/mL peni-
cillin and 100 μg/mL streptomycin and supplemented
with 10% fetal bovine serum at 37°C in a humidified
atmosphere of 5% CO2. At approximately 70-80% con-
fluence, the medium was preincubated with 1% bovine
serum albumin (BSA)-DMEM with 0.5 mM oleic acid
for 24 h. The fatty acid-BSA complex was prepared as
described by Van Harken et al [28]. The cellular protein
concentration was determined using the method of
Lowry et al [29] or the bicinchoninic acid method [30].
To measure cytotoxicity, 3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyl tetrazolium bromide (MTT) activity was deter-
mined using a MTT Cell Growth Kit (CHEMICON
International, Inc., Temecula, CA, U.S.A.); and after 24-
h incubation with 1-10 mg/mL of the soy peptides, the
MTT activity of HepG2 cells was unaffected in all
experiments (data not shown).
Measurement of cellular TG synthesis
To evaluate the effects of the peptides on cellular TG
synthesis, HepG2 cells were preincubated with 1%
BSA-DMEM with 0.5 mM oleic acid for 24 h and then
incubated with experimental medium (Control: 1% BSA-
DMEM; Peptides: 1% BSA-DMEM with 1-10 mg/mL
peptides) containing 18.5 KBq [1-
14C] acetate (American
Radiolabeled Chemicals, St. Louis, MO, USA) for 24 h.
After incubation, cells were washed once and collected
in 2 mL of phosphate-buffered saline using a rubber
policeman. Cells were thawed and homogenized with a
sonicator (Sonifier 250TM; Branson Ultrasonic Co., CT,
USA) before analysis. Total lipids in the cells were
extracted and purified by the method of Bligh and Dyer
[31], then radioactivities were measured by a liquid scin-
tillation counter (Wallic System 1410; Pharmacia,
Uppsala, Sweden). The lipids were fractionated using
thin-layer chromatography (TLC) in a solvent mixture
of petroleum ether:diethyl ether:acetate (82:18:1, v/v/v).
After separation with TLC, the radioactivities of the
lipid fractions were quantitated with a bio-imaging ana-
lyzer (BAS1000; Fuji Photo Film, Kanagawa, Japan).
Activity of TG synthesis was calculated as “cpm per mg
protein” and represented as “% of control” in figures.
Measurement of apolipoprotein B100 secretion
To evaluate the effects of the di-peptides on apolipopro-
tein B100 (apoB100) secretion, HepG2 cells were prein-
cubated with 1% BSA-DMEM with 0.5 mM oleic acid
for 24 h and further incubated with experimental med-
ium (Control: 1% BSA-DMEM; Peptides: 1% BSA-
DMEM with 5 mg/mL di-peptides) for 24 h. At the end
of the experiment, the media were harvested for the
measurement of apoB100 levels, and the cells were used
for determination of cellular protein levels. ApoB100
levels in the culture media were quantitated using the
ApoB Microwell ELISA Assay Kit (AlerCHEK).
Animals and diets
All aspects of the animal experiment were conducted
according to the guidelines provided by the ethical com-
mittee of experimental animal care at Saga University.
Male OLETF rats aged 4 weeks were provided by the
Tokushima Research Institute (Otsuka Pharmaceutical,
Tokushima, Japan). The rats were housed individually in
metal cages in a temperature-controlled room (24°C)
under a 12-h light/dark cycle. In the first animal experi-
ment, the rats were assigned to 1 of 2 groups (6 rats
each), and were fed 1 of 2 diets: (i) a semi-synthetic diet
containing (in weight %) casein, 20; corn oil, 7; corn-
starch, 15; vitamin mixture (AIN-76™), 1; mineral mix-
ture (AIN-76™), 3.5; DL-methionine, 0.3; choline
bitartrate, 0.2; cellulose, 5; and sucrose, 48 (control diet,
Con); (ii) a semi-synthetic diet containing (in weight %)
SCP-LD3, 19.1; corn oil, 7; cornstarch, 15; vitamin mix-
ture, 1; mineral mixture, 3.5; DL-methionine, 0.3; cho-
l i n eb i t a r t r a t e ,0 . 2 ;c e l l u l o s e ,5 ;a n ds u c r o s e ,4 8 . 9( s o y
peptide diet, SoyPep) for 2 weeks. In the second animal
experiment, the rats were a s s i g n e dt o1o f3g r o u p s( 6
rats each) and were fed 1 of the following 3 diets: (i)
Figure 2 Reversed phase-high performance liquid
chromatography elution profile of 0% CH3CN/0.1%TFA fraction
peptides on COSMOSIL 5C18-AR-II column and identification of
di-peptides.
Inoue et al. Lipids in Health and Disease 2011, 10:85
http://www.lipidworld.com/content/10/1/85
Page 3 of 10control diet; (ii) soy peptide diet; and (iii) a semi-syn-
thetic diet containing (in weight %) hydrophilic peptide,
11.85; casein, 10; corn oil, 7; cornstarch, 15; vitamin
mixture, 1; mineral mixture, 3.5; DL-methionine, 0.3;
choline bitartrate, 0.2; cellulose, 5; and sucrose, 46.15
(hydrophilic peptide diet) for 4 weeks. Basal semisyn-
thetic diets were prepared according to recommenda-
tions of the AIN-76 [32].
Measurement of TG levels in serum and liver
All rats were killed by aortic exsanguination under
diethyl ether anesthesia, and the liver was excised for
analysis. The serum was separated from the blood, and
serum TG levels were measured using a commercial
enzyme assay kit (Wako Pure Chemicals, Tokyo, Japan).
Hepatic lipid was extracted according to the method of
Folch et al. [33], and the TG concentration was mea-
sured by the method of Fletcher [34].
Preparation of hepatic subcellular fractions
A piece of liver from each rat was homogenized in 6
volumes of a 0.25 M sucrose solution containing 1 mM
ethylenediaminetetraacetic acid in a 10 mM Tris-HCl
buffer (pH 7.4). After the nuclear fraction was precipi-
tated, the supernatant was centrifuged at 10,000 × g for
10 min at 4°C to obtain mitochondrial fractions. The
resulting supernatant was recentrifuged at 125,000 × g
for 60 min to precipitate microsomes, and the remaining
supernatant constituted the cytosol fraction. The protein
concentration was determined according to the method
of Lowry et al. [29], with BSA used as the standard.
Assays of hepatic enzyme activity
The enzyme activity of phosphatidate phosphohydrolase
(PAP) [35], fatty acid synthase (FAS) [36], malic enzyme
[37], glucose 6-phosphate dehydrogenase (G6PDH) [38],
and carnitine palmitoyltransferase (CPT) [39] was deter-
mined as described elsewhere.
Statistical analysis
All values are expressed as mean ± SE. Data were ana-
lyzed by student t-test to assess differences between 2
groups. To assess differences between 3 groups, data
were analyzed by 1-way ANOVA, and all differences
were analyzed by the Tukey-Kramer post-hoc test
(KaleidaGraph, Synergy Software, Reading, PA). Differ-
ences were considered significant at P < 0.05.
Results and discussion
The liver is the pivotal organ concerned with lipid meta-
bolism. Nonalcoholic fatty liver disease (NAFLD) is
often associated with features of the metabolic syn-
drome and is emerging as the most common liver dis-
ease worldwide [40-42]. NAFLD is the preferred term
used to describe the spectrum of liver damage, ranging
from hepatic steatosis to steatohepatitis, liver fibrosis,
and cirrhosis. Most liver-related morbidity and mortality
events are associated with the development of cirrhosis.
Cirrhosis is most likely to occur in individuals who have
progressed from hepatic steatosis to steatohepatitis.
Although the processes through which steatohepatitis
evolves from hepatic steatosis are not fully understood,
it is necessary to develop effective therapies for the
treatment of NAFLD, and the discovery of nutrients
that reduce the risk of NAFLD would be useful. We
previously discovered novel hypolipidemic dietary com-
ponents such as functional lipids and phytochemicals by
in vitro (HepG2 cells) and in vivo (OLETF rats) evalua-
tion [43-47].
Effects of SCP-LD3 on lipid metabolism in HepG2 cells
and OLETF rats
In the first part of the current study, we evaluated the
effects of SCP-LD3 treatment on TG synthesis in HepG2
cells. As shown in Figure 3A, incorporation of [1-
14C]
acetate into the cellular TG fraction was significantly low-
ered by SCP-LD3 treatment. These results suggest that
SCP-LD3 has the ability to normalize lipid abnormalities
possibly through the suppression of TG synthesis in hepa-
tocytes. Next, we evaluated the effects of SCP-LD3 on
lipid metabolism in OLETF rats. As shown in Figure 3B,
2-week feeding of SCP-LD3 alleviated the obesity-induced
TG accumulation in the liver of OLETF rats without sig-
nificant alterations in other growth parameters such as
food intake (control, 29.2 ± 0.6 g/day; SCP-LD3, 29.0 ± 0.6
g/day) and final body weight (control, 539 ± 12 g; SCP-
LD3, 531 ± 17 g). Additionally, serum TG level was also
lowered by SCP-LD3 feeding in OLETF rats (control, 251
Figure 3 Effects of soy crude peptide (SCP)-LD3 on triglyceride
(TG) synthesis in HepG2 cells (1 mg/mL) and hepatic TG level
in Otsuka Long-Evans Tokushima fatty (OLETF) rats. Values are
expressed as mean ± standard error of 5 samples in vitro and 6 rats
in vivo. Asterisks indicate a significant difference at P < 0.05.
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Page 4 of 10± 40 mg/dL; SCP-LD3, 143 ± 21 mg/dL, P < 0.05). These
results indicate that SCP-LD3 has TG-lowering properties,
which led us to perform further isolation and identification
of hypolipidemic peptide sequences from this peptide dur-
ing subsequent experiments.
Effects of hydrophobic and hydrophilic fractions on lipid
metabolism in HepG2 cells and OLETF rats
Several reports have suggested that the amino acid com-
position of dietary proteins and peptides influences their
bioactivities [11]. It has been reported that high
amounts of histidine and hydrophobic amino acids con-
tribute to antioxidant potency and that hydrophobic
peptides can bind bile acids, thereby enhancing fecal
steroid excretion [20,48-50]. In the second part of the
current study, we evaluated the effects of hydrophobic
and hydrophilic fractions, separated from SCP-LD3 with
hydrophobic synthetic absorbent, on TG synthesis in
HepG2 cells. As shown in Table 1, the hydrophobic
fraction was found to contain a higher amount of phe-
nylalanine, whereas the hydrophilic fraction contained a
higher amount of glutamine compared to SCP-LD3. In
HepG2 cells, incorporation of [1-
14C] acetate into the cel-
lular TG fraction was significantly and dose-dependently
lowered by hydrophilic fraction treatment (Figure 4A). In
the next in vivo experiment, we evaluated the effects of
the hydrophilic fraction on lipid metabolism in OLETF
rats. Though there was no significant alteration in growth
parameters (Table 2), feeding of the hydrophilic fraction
alleviated hepatomegaly and hepatic TG accumulation in
O L E T Fr a t s( T a b l e2 ,F i g u r e4 B ) .M o r e o v e r ,d e s p i t et h e
fact that the degree of supplementation with the hydrophi-
lic fraction in the diet (substituted for 10% casein) was half
that of SCP-LD3 (substituted for 20% casein), the TG-
lowering effects of these 2 diets were almost the same. In
agreement with the in vitro study, the TG-lowering effects
were attributable to the suppression of fatty acid synthesis
(represented by lowered activities of FAS, G6PDH, and
malic enzyme) and TG synthesis (represented by lowered
PAP activity) in the liver of OLETF rats.
Effects of peptides fractionated by GPC-HPLC on TG
synthesis and apoB100 secretion in HepG2 cells
It has been shown that short peptides, mostly di-, tri-,
and tetra-peptides, are absorbed more rapidly than free
amino acids and that short peptides are absorbed intact
by specific peptide transporters such as PepT1 and
PepT2 into the blood circulation and transported to tar-
get organs [51-54]. Intact absorption of the hypotensive
dipeptide Val-Tyr, for example, was confirmed in rats
and humans [55-57]. In the third part of the current
study, we evaluated the effects of di- or tri-peptide frac-
tions, separated from the hydrophilic fraction with GPC-
HPLC (Figure 1), on TG synthesis in HepG2 cells. As
shown in Figure 5A, all 3 fractions lowered the incor-
poration of [1-
14C] acetate into the cellular TG fraction
significantly and dose-dependently. It is known that
blood apoB100 level is positively correlated with the inci-
dence of coronary heart disease and that enhanced secre-
tion of apoB100 by the liver is a biomarker of hepatic
lipid abnormality [58-60]. Therefore, dietary components
that control the rate of apoB100 secretion by the liver are
of great interest [61-63]. In the current study, we evalu-
ated the effects of Frc-B and Frc-C treatment on
apoB100 secretion from HepG2 cells. Our results show
that Frc-C treatment, but not Frc-B treatment, induced a
33% reduction of apoB100 secretion compared with the
control medium (Figure 5B).
Effects of peptides fractionated by ODS column
chromatography on TG synthesis and apoB100 secretion
in HepG2 cells
In the fourth part of the current study, we evaluated the
effects of peptide fractions, separated from the Frc-C
peptide with ODS column chromatography, on TG
synthesis and apoB100 secretion in HepG2 cells. Our
results show that 0% CH3CHCN/0.1% TFA fraction low-
ered both TG synthesis and apoB100 secretion, but 20%
CH3CHCN/0.1% TFA fraction lowered only TG synth-
esis, in HepG2 cells (Figure 6A, B).
Effects of synthesized di-peptides on TG synthesis and
apoB100 secretion in HepG2 cells
Finally, 0% CH3CN/0.1% TFA fraction peptides were
separated by reverse-phase HPLC, where by 7 di-pep-
tides were identified (Figure 2). Six di-peptides (Ala-Leu,
Ala-Tyr, Ala-Val, Lys-Ala, Ser-Tyr, and Val-Lys), but
not Leu-Val, could be synthesized, and we evaluated the
Figure 4 Effects of soy peptides on triglyceride (TG) synthesis
in HepG2 cells (1 or 10 mg/mL) and hepatic TG level in Otsuka
Long-Evans Tokushima fatty (OLETF) rats. Values are expressed
as mean ± standard error of 5 samples in vitro and 6 rats in vivo.
Different letters indicate a significant difference at P < 0.05.
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apoB100 secretion in HepG2 cells. We found that 3 di-
peptides, Ser-Tyr, Val-Lys, and Lys-Ala, reduced TG
synthesis (Figure 7A), and Ser-Tyr additionally reduced
apoB secretion (Figure 7B) in HepG2 cells. The pre-
sence of 3 di-peptide sequences in the amino acid
sequence of soybean components such as glycinin, the
BCG alpha subunit (BCG-a) ,t h eB C Ga l p h ap r i m e
subunit (BCG-a’), the BCG beta subunit (BCG-b), the
trypsin inhibitor, and lipoxygenase is shown in Table 3.
The presence of the Ser-Tyr sequence is recognized in
the amino acid sequence of glycinin, BCG-a,B C G - a’,
BCG-b, and lipoxygenase. The presence of the Val-Lys
sequence is recognized in the amino acid sequence of
glycinin, the trypsin inhibitor, and lipoxygenase. The
presence of the Lys-Ala sequence is recognized in the
amino acid sequence of glycinin, BCG-a,B C G - a’,
BCG-b, the trypsin inhibitor, and lipoxygenase.
Because of the suppressive effects on both lipogenesis
and apoB100 secretion in HepG2 cells and the fre-
quent presence in the amino acid sequence of major
soybean components, we speculate that Ser-Tyr is the
most effective TG-lowering constituent of soy protein
isolate-derived peptides.
Conclusion
We appear to have isolated novel active peptides with
TG-lowering effects from soy protein, including Lys-Ala,
Val-Lys, and Ser-Tyr, using in vitro and in vivo screen-
ing systems (Figure 8). The physiological properties of
these isolates would be, at least in part, attributable to
suppressed lipogenesis in the liver. Further studies are
necessary to evaluate the effects of these 3 di-peptides
on lipid abnormalities in vivo and to determine the low-
est effective concentration.
Figure 5 Effects of fractionated soy peptides (1 or 5 mg/mL)
on triglyceride (TG) synthesis and apolipoprotein (Apo) B100
secretion in HepG2 cells. Values are expressed as mean ± standard
error of 5 samples. Different letters indicate a significant difference
at P < 0.05.
Table 2 Effects of dietary soy peptides on growth parameters and activities of hepatic triglyceride metabolism-related
enzymes in Otsuka Long-Evans Tokushima fatty rats
Control Soy crude peptide-LD3 Hydrophilic peptide
Initial body weight (g) 465 ± 11 467 ± 7 463 ± 9
Final body weight (g) 558 ± 10 554 ± 7 550 ± 8
Food intake (g) 743 ± 3 740 ± 8 738 ± 10
Liver weight (g/100 g b.w.) 3.45 ± 0.05
a 3.14 ± 0.05
b 3.16 ± 0.06
b
Hepatic enzyme activity (nmol/min/mg protein)
FAS 17.0 ± 0.7
a 13.6 ± 0.8
b 13.3 ± 1.3
b
G6PDH 127 ± 7
a 82.7 ± 4.2
b 77.0 ± 5.2
b
Malic enzyme 115 ± 5
a 79.0 ± 3.7
b 86.5 ± 2.1
b
PAP 17.3 ± 1.1
a 14.5 ± 0.5
b 14.8 ± 0.5
b
CPT 5.16 ± 0.31 5.66 ± 0.25 5.42 ± 0.10
FAS, fatty acid synthase; G6PDH, glucose 6-phosphate dehydrogenase; PAP, phosphatidate phosphohydrolase; CPT, carnitine palmitoyltransferase.
Values are expressed as mean ± standard error of 6 rats.
Different superscript letters indicate a significant difference at P < 0.05.
Figure 6 Effects of fractionated soy peptides (5 mg/mL) on
triglyceride (TG) synthesis and apolipoprotein (Apo) B100
secretion in HepG2 cells. Values are expressed as mean ± standard
error of 5 samples. Different letters indicate a significant difference
at P < 0.05.
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Page 6 of 10Figure 7 Effects of synthesized di-peptides (5 mg/mL) on triglyceride (TG) synthesis and apolipoprotein (Apo) B100 secretion in
HepG2 cells. Values are expressed as mean ± standard error of 5 samples. Different letters indicate a significant difference at P < 0.05.
Table 3 Amino acid sequence of major components in soy protein
Glycinin [Glycine max (soybean)]/CAA37044
MGKPFTLSLSSLCLLLLSSACFAISSSKLNECQLNNLNALEPDHRVEFEGGLIQTWNSQHPELKCAGVTVSKLTLNRNGLHLPSYSPYPRMIIIAQGKGALQCKPGCPETFE
EPQEQSNRRGSRSQKQQLQDSHQKIRHFNEGDVLVIPPGVPYWTYNTGDEPVVAISLLDTSNFNNQLDQTPRVFYLAGNPDIEYPETMQQQQQQKSHGGRKQGQHQ
QEEEEEGGSVLSGFSKHFLAQSFNTNEDIAEKLQSPDDERKQIVTVEGGLSVISPKWQEQQDEDEDEDEDDEDEQIPSHPPRRPSHGKREQDEDEDEDEDKPRPSRPSQ
GKREQDQDQDEDEDEDEDQPRKSREWRSKKTQPRRPRQEEPRERGCETRNGVEENICTLKLHENIARPSRADFYNPKAGRISTLNSLTLPALRQFQLSAQYVVLYKN
GIYSPHWNLNANSVIYVTRGQGKVRVVNCQGNAVFDGELRRGQLLVVPQNFVVAEQAGEQGFEYIVFKTHHNAVTSYLKDVFRAIPSEVLAHSYNLRQSQVSELKYEGN
WGPLVNPESQQGSPRVKVA
Beta-conglycinin alpha subunit [Glycine max (soybean)]/BAE46788
MMRARFPLLLLGLVFLASVSVSFGIAYWEKENPKHNKCLQSCNSERDSYRNQACHARCNLLKVEKEECEEGEIPRPRPRPQHPEREPQQPGEKEEDEDEQPRPIPFPRPQ
PRQEEEHEQREEQEWPRKEEKRGEKGSEEEDEDEDEEQDERQFPFPRPPHQKEERKQEEDEDEEQQRESEESEDSELRRHKNKNPFLFGSNRFETLFKNQYGRIRVLQRF
NQRSPQLQNLRDYRILEFNSKPNTLLLPNHADADYLIVILNGTAILSLVNNDDRDSYRLQSGDALRVPSGTTYYVVNPDNNENLRLITLAIPVNKPGRFESFFLSSTEAQQ
SYLQGFSRNILEASYDTKFEEINKVLFSREEGQQQGEQRLQESVIVEISKEQIRALSKRAKSSSRKTISSEDKPFNLRSRDPIYSNKLGKFFEITPEKNPQLRDLDIFLSIVDMNE
GALLLPHFNSKAIVILVINEGDANIELVGLKEQQQEQQQEEQPLEVRKYRAELSEQDIFVIPAGYPVVVNATSNLNFFAIGINAENNQRNFLAGSQDNVISQIPSQVQELA
FPGSAQAVEKLLKNQRESYFVDAQPKKKEEGNKGRKGPLSSILRAFY
Beta-conglycinin alpha prime subunit [Glycine max (soybean)]/BAB64303
MMRARFPLLLLGVVFLASVSVSFGIAYWEKQNPSHNKCLRSCNSEKDSYRNQACHARCNLLKVEEEEECEEGQIPRPRPQHPERERQQHGEKEEDEGEQPRPFPFPRP
RQPRQEGEHEQKEEHEWHRKEEKHGGKGSEEEQDGREHPRPHQPHQKEEEKHEWQHKQEKHQGKESEEEEEDQDEDEEQDKESQESEGSESQREPRRHKNKNPFHF
NSKRFQTLFKNQYGHVRVLQRFNKRSQQLQNLRDYRILEFNSKPNTLLLPHHADADYLIVILNGTAILTLVNNDDRDSYNLQSGDALRVPAGTTYYVVNPDNDENLRM
ITLAIPVNKPGRFESFFLSSTQAQQSYLQGFSKNILEASYDTKFEEINKVLFGREEGQQQGEERLQESVIVEISKKQIRELSKRAKSSSRKTISSEDKPFNLRSRDPIYSNKLGKL
FEITPEKNPQLRDLDVFLSVVDMNEGALFLPHFNSKAIVVLVINEGEANIELVGIKEQQQRQQQEEQPLEVRKYRAELSEQDIFVIPAGYPVVVNATSDLNFFAFGINAEN
NQRNFLAGSKDNVISQIPSQVQELAFLGSAKDIENLIKSQSESYFVDAQPQQKEEGNKGRKGPLSSILRAFY
Beta-conglycinin beta subunit [Glycine max (soybean)]/BAB64306
MMRVRFPLLVLLGTVFLASVCVSLKVREDENNPFYFRSSNSFQTLFENQNGRIRLLQRFNKRSPQLENLRDYRIVQFQSKPNTILLPHHADADFLLFVLSGRAILTLVN
NDDRDSYNLHPGDAQRIPAGTTYYLVNPHDHQNLKIIKLAIPVNKPSRYDDFFLSSTQAQQSYLQGFSHNILETSFHSEFEEINRVLFGEEEEQRQQEGVIVELSKEQIRQLS
RRAKSSSRKTISSEDEPFNLRSRNPIYSNNFGKFFEITPEKNPQPRDLDIFLSSVDINEGALLLPHFNSKAIVILVINEGDANIELVGIKEQQQKQKQEEEPLEVQRYRAELSE
DDVFVIPAAYPFVVNATSNLNFLAFGINAENNQRNFLAGEKDNVVRQIERQVQELAFPGSAQDVERLLKKQRESYFVDAQPQQKEEGSKGRKGPFPSILGALY
Trypsin inhibitor [Glycine max (soybean)]/AAF87095
MPSTWGAAGGGLKLGRTGNSNCPVTVLQDYSEIFRGTPVKFSIPGISPGIIFTGTPLEIEFAEKPYCAESS KWVAFVDNEIQKACVGIGGPEGHPGQQTFSGTFSIQKY
KFGYKLVFCITGSGTCLDIGRFDAKNGEGG RRLNLTEHEAFDIVFIEASKVDGIIKSVV
Lipoxygenase [Glycine max (soybean)]/CAA39604
MFGIFDKGQKIKGTVVLMPKNVLDFNAITSIGKGGVIDTATGILGQGVSLVGGVIDTATSFLGRNISMQLISATQTDGSGNGKVGKEVYLEKHLPTLPTLGARQDAFSIF
FEWDASFGIPGAFYIKNFMTDEFFLVSVKLEDIPNHGTIEFVCNSWVYNFRSYKKNRIFFVNDTYLPSATPAPLLKYRKEELEVLRGDGTGKRKDFDRIYDYDVYNDLGN
PDGGDPRPILGGSSIYPYPRRVRTGRERTRTDPNSEKPGEVYVPRDENFGHLKSSDFLTYGIKSLSHDVIPLFKSAIFQLRVTSSEFESFEDVRSLYEGGIKLPTDILSQISPL
PALKEIFRTDGENVLQFPPPHVAKVSKSGWMTDEEFAREVIAGVNPNVIRRLQEFPPKSTLDPTLYGDQTSTITKEQLEINMGGVTVEEALSTQRLFILDYQDAFIPYLTR
INSLPTAKAYATRTILFLKDDGTLKPLAIELSKPHPDGDNLGPESIVVLPATEGVDSTIWLLAKAHVIVNDSGYHQLVSHWLNTHAVMEPFAIATNRHLSVLHPIYKLLYPHYR
DTININGLARQSLINADGIIEKSFLPGKYSIEMSSSVYKNWVFTDQALPADLVKRGLAIEDPSAPHGLRLVIEDYPYAVDGLEIWDAIKTWVHEYVSLYYPTDAAV
QQDTELQAWWKEAVEKGHGDLKEKPWWPKMQTTEDLIQSCSIIVWTASALHAAVNFGQYPYGGLILNRPTLARRFIPAEGTPEYDEMVKNPQKAYLRTITPKFETL
IDLSVIEILSRHASDEIYLGERETPNWTTDKKALEAFKRFGSKLTGIEGKINARNSDPSLRNRTGPVQLPYTLLHRSSEEGLTFKGIPNSISI
Definition [source]/Accession number. Lys-Ala, KA; Ser-Tyr, SY; Val-Lys, VK.
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